RE:RE:RE:RE:RE:Disappointment ContinuesI think MedX is executing on their strategy that I laid out on my earlier post.
I think DermTech shares traded from Aug,2017- Dec 2020 from $19.40-$11.49 loosing lots of money. Then they announced their platform with a few clinical papers and their shares took off. Last quarter they lost $15.1 million so I think your statements earning investors money are a bit misguided.If you are referring to share price appreciation as always it depends on when you invested.
Mexico is a fair point however I would suggest COVID is very real and it is slowing down a normally slow regulatory proceedues. MedX is in 35 countries I am sure they know how to get through the regulatory process in Mexico. MedX does communicate to investors, you seem to be the only poster who cannot get through to their IR company.
Here is the contact site; https://www.venturenorthcapital.com/